Use of thiadiazolo[4,3-a]pyridine derivatives

Details Use of thiadiazolo[4,3-a]pyridine derivatives Use of thiadiazolo[4,3-a]pyridine derivatives

2000-10-05

2001-12-04

Huang, Evelyn Mei (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S293000, C546S114000, C546S083000

Reexamination Certificate

active

06326378

ABSTRACT:

This application is the national phase of PCT/EP99/00886, filed Feb. 11, 1999.
The present invention relates to the use of thiadiazolo[4,3-a]pyridine derivatives for the production of medicaments for the treatment of diseases which are modulated by the inhibition of phosphodiesterase(s) (PDE). The invention relates in particular to the use of substances having a great therapeutic breadth with preferred inhibition of phosphodiesterases of types III and IV, preferably of type IV.
Previously disclosed PDE IV inhibitors caused unpleasant side effects in experimental animals and in man, such as production of, for example, nausea, giddiness and vomiting, as well as undesired cardiovascular effects such as lowering of blood pressure and tachycardia. However, compounds of the general formula I showed a great therapeutic breadth in in-vivo animal models. The side effects of previously known PDE IV inhibitors can thus be markedly decreased.
The compounds according to the invention are thiadiazolo[4,3-a]pyridine derivatives of the general formula I
in which
X
1
and X
2
, identically or differently, are hydrogen, a C
1
- to C
6
-alkyl radical or a halogen atom or, if they are in adjacent positions, form a fused phenyl ring together with the carbon atoms carrying them, and
R is a carbocyclic or heterocyclic saturated or unsaturated radical, which if desired can be mono- or polysubstituted by halogen, cyano, nitro, C
1
- to C
6
-alkyl, C
1
- to C
6
-haloalkyl, hydroxyl, C
1
- to C
6
-alkoxy, methylenedioxy, C
1
- to C
6
-alkylthio, C
1
- to C
6
-haloalkylthio, amino, C
1
- to C
6
-alkylamino, C
2
- to C
12
-dialkylamino, pyrrolyl, carboxyl, carbamoyl, benzyl C
1
- to C
6
-hydroxyalkyl, C
2
- to C
7
-carboxyalkyl, C
2
- to C
7
-alkoxycarbonyl-C
1
- to C
6
-alkyl, carbamoyl-C
1
- to C
6
-alkyl, N-hydroxy-N—C
1
- to C
6
-alkylcarbamoyl-C
1
- to C
6
-alkyl or C
2
- to C
6
-alkenyl, and their physiologically tolerable salts.
The alkyl radicals in the mentioned alkyl, alkoxy, alkylthio and (di)alkylamino groups and also the alkenyl radicals can be straight-chain or branched. Preferred alkyl radicals in these groups are the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and 3-pentyl radical, preferred alkenyl radicals are the vinyl and the allyl radical.
A C
1
-C
6
-haloalkyl radical is preferably trifluoromethyl.
Possible halogen atoms are fluorine, chlorine and bromine.
Carbocyclic radicals are the phenyl, cyclohexyl and cyclopentyl radical. Possible heterocyclic radicals are pyridyl, piperidinyl, pyrimidinyl, pyrrolidinyl, isoxazolyl, oxazolyl, thiazolyl, thiazolinyl, triazolyl and tetrazolyl radicals.
Preferred compounds of the formula I are compounds in which X
1
is hydrogen, methyl or chlorine, X
2
is hydrogen or X
1
and X
2
together form a fused phenyl ring and R is a phenyl ring which can be mono- or disubstituted by fluorine, chlorine, methyl, methoxy, tert-butyl, isopropoxy, trifluoromethyl, trifluoromethylthio, hydroxyl, nitrile, nitro, hydroxymethyl, methylenedioxy, diethylamino, methylthio, pyrrolyl, methoxycarbonylmethyl, carboxymethyl, N-hydroxy-N-methylcarbamoylmethyl or N-tetrazolylcarbamoylmethyl, or is a thiazolyl, pyridinyl, tetrazolyl, pyrimidyl or cyclohexyl radical.
Apart from the compounds mentioned in the examples, the invention relates in particular to all substances which have any possible combination of the substituents mentioned in the examples.
The synthesis of some of the compounds is described in WO 93/06109. Alternatively, a compound of the general formula II
in which X
1
and X
2
have the abovementioned meaning, can be reacted in a known manner either
a) with a compound of the formula III
ClSCCl
3
  (III),
 or a reactive derivative thereof and a compound of the general formula IV
H
2
N—R  (IV),
 in which R has the abovementioned meaning, or
b) with a compound of the general formula V
YS—CY═N—R  (V),
 in which R has the abovementioned meaning and Y is a halogen atom, and then, if desired, a radical R can be converted into another radical given by the definition and the compound of the formula I obtained, if desired, can be converted into a salt by reaction with physiologically tolerable acids or bases.
Possible halogen atoms for Y are, in particular, chlorine and bromine.
The process is preferably carried out in such a way that a compound of the general formula II is first condensed with a compound of the formula III and the product obtained is isolated. This intermediate is then reacted with a compound of the general formula IV.
Another variant consists in allowing the reaction mixture obtained from the reaction of a compound of the formula II with a compound of the formula III to react with a compound of the formula IV without isolation of the intermediate.
The reactions are expediently carried out in a solvent such as water, ether, a lower alcohol such as, for example, methanol or ethanol or a halogenated hydrocarbon such as dichloromethane or trichloromethane with addition of a base such as triethylamine or sodium carbonate at temperatures between −20 and 50° C., preferably between 0° C. and room temperature.
The compounds of the formulae II, IV and V are known from the literature or can easily be prepared by trivial methods starting from known compounds.
Conversion of a radical R into another radical R is carried out, for example, by ether cleavage using a protic acid or Lewis acid such as hydrogen bromide, hydrogen chloride, hydrogen iodide, aluminium trichloride, boron trichloride or by alkylation of a hydroxyl group using the desired alkyl halide or alkyl sulphate.
A carboxyl group contained in R can be converted into an ester group or carboxamide function, if desired by means of a reactive derivative such as a halide, imidazolide or anhydride; an ester group contained in R can be converted into the carboxyl group by acidic or basic hydrolysis and into the carboxamide group by aminolysis.
Possible pharmacologically tolerable salts are, in particular, alkali metal, alkaline earth metal and ammonium salts and optionally salts with non-toxic inorganic or organic acids such as, for example, hydrochloric acid, sulphuric acid, phosphoric acid, hydrobromic acid, acetic acid, lactic acid, citric acid, malic acid, benzoic acid, salicylic acid, malonic acid, maleic acid, succinic acid or diaminocaproic acid.
The salts are obtained in a customary manner, e.g. by neutralization of the compounds of the formula I using the appropriate alkali solutions or acids.
It is described in WO 93/06109 that the compounds of the formula I inhibit the antigen-mediated contraction of lung tissue strips and prevent the lethality of an endotoxin shock.
PDE inhibitors intervene in the signal transduction cascade mediated by cyclic adenosine monophosphate (cAMP). PDE IV isoenzymes are found in various tissues and leukocyte types. They prevent the activation of leukocytes, thus also, inter alia, the secretion of TNF-&agr; and can therefore also be used, for example, for treatment of cachexia.
The compounds of the formula I inhibit phosphodiesterase(s) (PDEs), preferably isoenzymes of the subclass type IV, with a simultaneous great therapeutic breadth. The compounds of the formula I are particularly suitable for medicaments for the preventive and/or symptomatic therapy of disorders whose causes lie in faulty regulation of intracellular signal transduction reactions which are controlled by cyclic nucleotides, in particular adenosine monophosphate (cAMP).
In particular, the compounds of formula I can be used for the production of medicaments for the treatment of disorders which are modulated by the inhibition of phosphodiesterase(s) (PDE) via cyclic nucleotides, especially cyclic adenosine monophosphate.
Examples of disorders which can be preventively or therapeutically treated by the compounds of the general formula I are: proliferatory disorders including tumours, lymphomas, leukaemias, atherosclerosis and glomerulopathies, furthermore disorders with reduction of learning abilit

Affiliated with

Also associated with

Rating

Use of thiadiazolo[4,3-a]pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of thiadiazolo[4,3-a]pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of thiadiazolo[4,3-a]pyridine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2567710